9月12日 - ** 药物开发商Apimeds Pharmaceuticals APUS.A股价盘前上涨26.5%，至2.48美元
** 周四晚些时候，该公司对 (link)。
** 该公司表示，美国食品及药物管理局的建议 (link)，有助于其主要非阿片类候选药物Apitox更快地通过临床试验并获得监管部门的批准。
** Apitox 正在开发用于治疗骨关节炎引起的慢性疼痛，骨关节炎会导致长期的关节损伤和活动能力下降。
** 截至上一交易日收盘，股价累计下跌 11.8%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.